I think this stock will recover some of it's losses, regardless of the outcome of the potential FDA restrictions on drug suggestions. The stock has a solid business model and the company has said they are seeing increased demand. This new fields of genetics testing still needs to establish itself in the healthcare payer ecosystem, which presents some risk, but all...
MYGN is setting up a long term H&S. An aggressive sell option is triggering today on the close below the old pivot low with the stop past the head. H&S will not trigger until a break of the neckline near $27. Aggressive right shoulder buy and sell's fail, but the greatly increased risk/reward can help offset.
MYGN Price broke out from 2 1/2 months of a base formation. A price gap of nearly 10% with very high volume occurred as a result of better-than-expected earnings. Unfortunately, we shouldn't expect the Tight Flag pattern to be powerful, since it is coming out of a base formation pattern, and not a powerful uptrend, but there should be enough upside potential to...
MYGN is another nice Flag formation with beautiful moneyflow accumulation. Anything close to $18 would be a good entry point or break of current label
* Trade Criteria *
Date First Found- February 19, 2017
Pattern/Why- Flag formation
Entry Target Criteria- Near $18 or Break of $18.67
Exit Target Criteria- Momentum
Stop Loss Criteria- $16.83
Please check...
As the price is revisiting the US$18.76 resistance, we may expect a short term pullback.
However, overall trend can be considered as positive. We may look for opportunity around the US$17-US$18 levels for accumulation.
Target: US$21.40-22.40, US$26.15-US$28.58.
Support: US$16.47
MYGN took a beating after it's guidance underwhelm last quarter.
I do believe that the reaction was overdone.
MYGN has healthy revenue streams and growing drug and generics demand.
TA confirms a re-entering into trading range of:
PT 1: $25.00 for a ~20%+ return.
PT 2: $30.00 for a 50% return.
Industry:Medical Equipment, Supplies & Distribution
Employees:2600
Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to enable optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
MYGN
